Check out important updates from the FDA for the week of September 2.

As Medicare open enrollment begins, the NCPA is urging CMS to facilitate appropriate PBM contracting for pharmacies in the upcoming plan year.

Findings were presented at the American Heart Association's Hypertension Scientific Sessions in Chicago, Illinois.

CRS3123 is a novel, small molecule, antibiotic drug candidate that selectively inhibits 1 form of the bacterial methionyl-tRNA synthetase enzyme and is not affected by resistance to any existing classes of antibiotics.

McKesson, Cardinal Health, and Cencora will share the settlement payment, resolving claims that the companies were significantly involved in fueling the US opioid epidemic.

DaylightRX from Big Health is a digital formulation of cognitive behavioral therapy and is available by prescription only.

Embecta’s new patch pump offers a larger insulin reservoir to better accommodate for the needs of patients with type 2 diabetes (T2D).

Click Therapeutics announced that CT-132 met its primary endpoint in the phase 3 ReMMi-D trial.

Dana Krug, Senior Vice President of Cold Chain Fulfillment at Phononic, explained the current state of his company’s cooling technology and the common trends of temperature control throughout the industry.

Bezisterim acts on inflammatory signaling pathways and may be a viable treatment option for post–COVID-19 condition, or long COVID.

Results from the PALISADE study were published in The New England Journal of Medicine.

The vaccine, VAX-31, targets 20 serotypes in common with PCV20, as well as 11 additional serotypes.

Results from HERCULES will form the basis for future discussions with global regulatory authorities, according to Sanofi.

The protein-based vaccine includes a monovalent component corresponding to the Omicron variant JN.1 strain.

Independent pharmacists, health care providers, community leaders, and law enforcement must all work together to address the fentanyl epidemic.

Catch up on important immunization news from the month of August.

In case you missed it, this week we had news about COVID-19 and the upcoming respiratory virus season, advancements in clinical trials for ASCVD, the first OTC birth control, and more.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

Chijioke Bennett, executive director of clinical development at Novavax, discusses how health care providers can increase awareness around the importance of COVID-19 vaccines.

Emergent BioSolutions has announced that it will donate 50,000 doses of ACAM2000 for potential deployment across affected areas in Central Africa.

Catch up on important diabetes news from the month of August.

Checkout these important FDA updates from the month of August 2024.

Results from the INTEGUMENT-OLE phase 3 trial showed the therapy was also well-tolerated, with no new safety signals observed during treatment of up to 56 weeks.

Stephanie Sober, MD, MSHP, investigator on the pivotal research that supported the prescription-to-OTC switch of Opill, shares insights on how the medicine is reshaping the reproductive landscape.

As research continues to uncover the potential benefits of psilocybin, pharmacists and other clinicians have an essential role in bridging ancient wisdom with contemporary science.